Shots:
- The VRBPAC voted 20-0, with one abstention that the benefits of the Moderna’s vaccine outweighed its risks for use in people aged ≥18yrs
- The recommendation is based on data analysis from the pivotal P-III clinical study that demonstrated 94.1% efficacy
- The US FDA’s committees provide non-binding recommendations. The FDA will take the VRBPAC’s recommendation into consideration in making a final decision on approval
Click here to read full press release/ article | Ref: Moderna | Image: Pharmaphorum
The post Moderna’s mRNA-1273 Receives the US FDA’s Advisory Committee Vote Supporting EUA Against COVID-19 first appeared on PharmaShots.